Cylembio combined with pembrolizumab showed improved median progression-free survival, especially in PD-L1–negative tumors, but narrowly missed statistical significance. The vaccine demonstrated a ...

Official support for free-threaded Python, and free-threaded improvements Python’s free-threaded build promises true parallelism for threads in Python programs by removing the Global Interpreter Lock ...

IO Biotech's phase 3 melanoma trial showed a strong PFS benefit, especially in true 1st-line and PD1-negative patients, despite narrowly missing statistical significance. I believe the FDA should ...

The key event here is the announcement that their pair of vaccines simultaneously targeting IDO and PD-L1 showed a nominal improvement in progression-free survival (PFS) compared with pembrolizumab ...

IO Biotech’s cancer vaccine has “narrowly” failed to beat Merck's blockbuster oncology drug Keytruda in a phase 3 melanoma trial, but the company remains hopeful of a path to approval. The New ...

NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT) today announces topline results from the pivotal Phase 3 trial of its investigational, immune-modulatory, off-the-shelf ...

NEW YORK, Aug. 10, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company, today announced the company will hold a conference call and webcast on Monday, August ...

After buying its independence from Square Enix in 2017, Hitman developer IO Interactive has managed to survive in an industry of escalating budgets and general turmoil as the premier self-published ...

It’s also launching new video and image AI models. It’s also launching new video and image AI models. is a senior reporter covering technology, gaming, and more. He joined The Verge in 2019 after ...